Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data. by Buhl, I.K. et al.
RESEARCH ARTICLE
Cell Line Derived 5-FU and Irinotecan Drug-
Sensitivity Profiles Evaluated in Adjuvant
Colon Cancer Trial Data
Ida Kappel Buhl1,2☯, Sarah Gerster3☯¤, Mauro Delorenzi3,4, Thomas Jensen2, Peter
Buhl Jensen2, Fred Bosman5, Sabine Tejpar6, Arnaud Roth7, Nils Brunner1,
Anker Hansen2, Steen Knudsen2*
1 Section for Molecular Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen,
Copenhagen, Denmark, 2 Medical Prognosis Institute, Hoersholm, Denmark, 3 Bioinformatics Core Facility,
SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland, 4 Ludwig Center for Cancer Research and
Oncology Department, University of Lausanne, Lausanne, Switzerland, 5 University of Lausanne, University
Institute of Pathology, Lausanne, Switzerland, 6 University Hospital Gasthuisberg, Digestive Oncology Unit,
Leuven, Belgium, 7 University Hospital of Geneva, Oncosurgery Unit, Geneva, Switzerland
☯ These authors contributed equally to this work.
¤ Current address: Swiss National Science Foundation, Bern, Switzerland
* steen@medical-prognosis.com
Abstract
Purpose
This study evaluates whether gene signatures for chemosensitivity for irinotecan and 5-fluo-
rouracil (5-FU) derived from in vitro grown cancer cell lines can predict clinical sensitivity to
these drugs.
Methods
To test if an irinotecan signature and a SN-38 signature could identify patients who benefit-
ted from the addition of irinotecan to 5-FU, we used gene expression profiles based on cell
lines and clinical tumor material. These profiles were applied to expression data obtained
from pretreatment formalin fixed paraffin embedded (FFPE) tumor tissue from 636 stage III
colon cancer patients enrolled in the PETACC-3 prospective randomized clinical trial. A 5-
FU profile developed similarly was assessed by comparing the PETACC-3 cohort with a
cohort of 359 stage II colon cancer patients who underwent surgery but received no adju-
vant therapy.
Results
There was no statistically significant association between the irinotecan or SN-38 profiles
and benefit from irinotecan. The 5-FU sensitivity profile showed a statistically significant
association with relapse free survival (RFS) (hazard ratio (HR) = 0.54 (0.41–0.71), p<1e-05)
and overall survival (HR = 0.47 (0.34–0.63), p<1e-06) in the PETACC-3 subpopulation. The
effect of the 5-FU profile remained significant in a multivariable Cox Proportional Hazards
model, adjusting for several relevant clinicopathological parameters. No statistically
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significant effect of the 5-FU profile was observed in the untreated cohort of 359 patients
(relapse free survival, p = 0.671).
Conclusion
The irinotecan predictor had no predictive value. The 5-FU predictor was prognostic in
stage III patients in PETACC-3 but not in stage II patients with no adjuvant therapy. This
suggests a potential predictive ability of the 5-FU sensitivity profile to identify colon cancer
patients who may benefit from 5-FU, however, any biomarker predicting benefit for adjuvant
5-FU must be rigorously evaluated in independent cohorts. Given differences between the
two study cohorts, the present results should be further validated.
Introduction
The antimetabolite 5-fluorouracil (5-FU) is the backbone in systemic treatment of primary and
metastatic colorectal cancer (CRC), with further activity in a wide range of solid tumors includ-
ing other gastrointestinal malignancies, breast cancer, head and neck cancers and ovarian car-
cinomas [1]. 5-FU treatment results in a survival benefit in the adjuvant setting of CRC [2] and
is most often combined with oxaliplatin [3]. In treatment of metastatic CRC, 5-FU is currently
combined with either the topoisomerase-1 inhibitor irinotecan as FOLFIRI regimen or with
oxaliplatin as a FOLFOX regimen [4;5].
Competing variables on both tumor cell level and patient level may ensure or corrupt the
efficacy of 5-FU [6] and/or irinotecan [7] and with many patients not obtaining the benefit but
only the side effects of such treatment, there is an unmet need for predictive biomarkers [8].
Research on predictors of 5-FU response has mainly focused on thymidylate-synthase (TS) as a
target for 5-FU and of levels of the enzyme dihydropyrimidine dehydrogenase (DPD) which
metabolizes 5-FU in the liver [9–11]. Overall, conflicting results associations with treatment
effect compromise the usefulness of TS and DPD as predictors for 5-FU [12;13]. Similarly,
despite many attempts, no irinotecan predictive biomarkers have reached a level of evidence
allowing for routine clinical use [14].
We approached the problem of predicting 5-FU or irinotecan benefit based on gene expres-
sion data by comparing associations between gene expression profiles and efficacy of the drugs
in question in the National Cancer Institute US cell line repository NCI60 [15]. Models of sen-
sitivity for these drugs were developed prior to the present study by the Medical Prognosis
Institute (MPI), Denmark [16]. A second step included filtering the identified gene expression
profiles against mRNA expression from a collection of 3200 human tumors. Only genes being
differentially expressed in the clinical tumor material were retained in the models. An analo-
gously constructed prediction method has recently been externally validated by biostatisticians
fromMD Anderson for methotrexate in acute lymphoblastic leukemia, for ABVD (doxorubi-
cin, bleomycin, vinblastine, dacarbazine) in Hodgkin’ s lymphoma and for epirubicin in breast
cancer in three separate pre-specified clinical data sets [17]. Similar models were recently tested
for fulvestrant in breast cancer [18] and R-CHOP (rituximab, cyclophosphamide, doxorubui-
cin, vincristine, prednisone) in diffuse large B-cell lymphoma (DLBCL) [19].
In the present study we assessed a 5-FU and an irinotecan MPI sensitivity predictor. We
used gene expression and clinical patient data from the PETACC-3 colon cancer (CC) patient
subpopulation [20] and from a population of stage II CC patients who had undergone surgery
but received no adjuvant therapy [21] profiled on the same microarray platform. In the
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PETACC-3 prospective randomized clinical trial, the primary objective was to investigate
whether the addition of adjuvant irinotecan to adjuvant 5-FU + leucovorin (LV5FU) would
improve relapse-free survival (RFS). The study concluded that adding irinotecan to LV5FU did
not significantly improve survival, but they observed a statistically non-significant trend in
favor of treatment with irinotecan in addition to LV5FU [20].
Conclusions from the present study were that there was no association between the irinote-
can sensitivity predictor and patient outcome while the data suggest the 5-FU response profile
does correlate with outcomes of patients receiving 5-FU-based adjuvant therapy. These data
justify further clinical evaluation of the 5-FU response profile.
Patients and Methods
Predictor development based on in vitro assays
The in vitro based MPI method to develop a predictor of drug response has been described pre-
viously [16–19]. Briefly, it is an algorithm based on growth inhibition values (GI50) of the
NCI60 cell lines [15] subjected to treatment with either 5-FU, irinotecan or SN-38. SN-38 is
the active metabolite of irinotecan. Gene expression measurements were performed with an
Affymetrix HG-U133A array. After logit normalization, genes with a Pearson’s correlation
coefficient to GI50 above 0.25 or below -0.25 were considered as potential biomarkers of sensi-
tivity and resistance to treatment and retained to contribute to the profiles for 5-FU, irinotecan
or SN-38, respectively. To sort away genes only active in the in vitro setting mRNA measure-
ments from more than 3200 snap frozen clinical tumor samples were then applied to each pro-
file. Hereby, only markers already known to be present in patient tumors contributed to the
final profiles. Each signature consists of two sets of genes (up- and down-regulated features).
The profile scores were defined as the difference between the averages of the two groups of fea-
tures for each of the drugs. The scores were then scaled to cover the range from 0 to 100. A
sample was classified as sensitive to a treatment, if the corresponding normalized profile score
was larger than 50. All other samples were considered to be resistant.
The array (Almac Diagnostics Colorectal Cancer DSA) used for analysis of mRNA in the
FFPE patient samples is different from the array (HG-U133A) used for deriving the mRNA
profile in vitro. That required an additional translation of the profile from one array type to
another which was done by MPI before the profile was tested externally by SIB in the two study
populations.
The NCI has obtained the 60 cell lines from their sources as described https://dtp.cancer.
gov/default.htm [15;22].
Data sets and arrays
For the PETACC-3 data set, the gene expression profiles were generated from FFPE colorectal
cancer slides. The RNA extraction and hybridization was performed by the Almac group in
two batches. Data processing is described in detail in S1 Doc. The presented results are based
on 636 stage III samples.
The other cohort consisting of 359 CC stage II CC patients who had undergone surgery but
received no adjuvant therapy from Kennedy et al [21] were all examined for mRNA expression
similarly to the PETACC-3 samples. The cohort will hereafter be termed the Kennedy cohort.
Statistical analysis
The current project is a result of collaboration between two independent laboratories. The pro-
file conducted at Medical Prognosis Institute was sent to the Swiss Institute of Bioinformatics
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for all statistical analysis to be conducted there with a fully fixed testing procedure defined in
an analysis plan prior to the execution.
Relapse-free survival (RFS) was used as main end point to compare the results on both data
sets. RFS is defined as the time from the date of random allocation to the first date of relapse
(local, regional, or distant), the occurrence of a second primary CC, or death. Overall survival
(OS) as a secondary objective is defined as the time from the date of randomization to death of
any cause.
Additional variables in the multivariable analyses were treatment group, age, gender, tumor
site, T stage (T1-2, T3, and T4), N stage (N1 and N2) and tumor grade (G1-2 and G3-4),
KRAS mutation, BRAF mutation and microsatellite instability (MSI) when the variables were
available.
The analysis plan was designed to look for associations between prediction scores and clini-
cal outcome. Patients were discriminated in 2 groups based on the computed profile score.
Patients with a 5-FU profile score smaller or equal to 50 were labeled as poor prognosis (resis-
tant). The other patients were considered as good prognosis (sensitive) in relation to 5-FU
treatment.
A log-rank test was used to test the profile as a discrete variable comparing the survival
curves of patients predicted sensitive to those predicted resistant. Second, the plan was to
fit (multivariable) Cox Proportional Hazards models using the continuous profile scores.
Further, the hazard ratios for the 5-FU profile for relapse-free survival in the PETACC-3
and the Kennedy cohort were compared using a z-test. This is based on the assumptions that
with the null hypotheses that the two HR are equal, that the error distribution of the estimates
are normally distributed and that the two populations are comparable. However, it must be
stressed that the two populations represent two distinct cohorts with all the differences this can
lead to.
Results
Expression arrays and cell-line sensitivity data
The irinotecan profile derived from the NCI60 cell lines consisted of 38 positively correlated
genes and 32 negatively correlated genes. The genes were annotated to 353 positively correlated
and 166 negatively correlated ALMAC probe sets from the ALMAC Colorectal Cancer DSA
array. The 5-FU profile consisted of 91 positively correlated genes and 114 negatively corre-
lated genes. The probe sets from Affymetrix were mapped to 232 positively correlated and 437
negatively correlated probe sets from the ALMAC Colorectal Cancer DSA array.
The full list of probe sets and gene names for the irinotecan predictor appears from S1
Table; for the 5-FU predictor it is available as S2 Table.
Baseline patient characteristics
From the original PETACC-3 patient cohort, we identified a subgroup of 636 stage III CC
patients with available high quality mRNA expression data. This subgroup was used to test the
prognostic and predictive significance of the MPI irinotecan, SN-38 and 5-FU profiles, respec-
tively. Since the irinotecan and SN-38 data were almost identical we here only report on the iri-
notecan results. Baseline patient characteristics for the PETACC-3 study population and the
presently investigated subpopulation are reported in S3 Table parts A and B. It is seen that the
subpopulation was representative of the total stage III PETACC-3 study population. Further-
more, this subpopulation did not show major differences to the main PETACC-3 cohort
regarding benefit from adjuvant chemotherapy. Baseline patient characteristics for the Ken-
nedy cohort are presented in S3 Table part C.
5-FU and Irinotecan Predictive Biomarkers
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Association between irinotecan profile and baseline characteristics
S4 Table part A shows associations between the irinotecan predictive profile and several base-
line clinicopathological characteristics for the PETACC-3 subpopulation. We noticed a signifi-
cant association between the MSI/MSS status and the profile score in the subpopulation of the
PETACC-3 study. This was not taken into account for the subsequent analysis.
The irinotecan gene expression profile and patient prognosis
S4 Table part B shows that there was no statistically significant effect of the irinotecan score on
RFS (HR = 0.93; 95% CI = (0.77, 1.12); P = 0.450, N = 558) when tested in the total subgroup.
The results for OS are given in S4 Table part C.
In order to test for a potential interaction between the profile score and the treatment
group, we fitted models including an interaction term for RFS and for OS (outcome ~ treat-
ment_group + profile_score + treatment_group:profile_score). For the irinotecan profile, none
of the three terms led to a HR statistically significantly different from 1 (for OS and RFS, se S4
Table part D).
Kaplan Meier survival curves for the irinotecan profile are presented as S1 Fig. This profile
score was not associated with a difference in survival neither for RFS (Panel A, HR = 1.07;
95% CI = (0.81, 1.41); P = 0.65; N = 636) nor OS (Panel B, HR = 1.14; 95% CI = (0.82, 1.57);
P = 0.43; N = 636)).
Subgroup analyses
A significant separation of groups in favor of a high sensitivity score was neither obtained
when comparing the irinotecan profile with RFS in the “5-FU only” (no irinotecan added)
treatment group (HR = 0.89; 95% CI = (0.6, 1.31); P = 0.55; N = 307), with RFS in FOLFIRI
treatment group (HR = 1.28; 95% CI = (0.86, 1.91); P = 0.23; N = 329), with OS in “5-FU only”
treatment group (HR = 0.83; 95% CI = (0.53, 1.3); P = 0.41; N = 307) nor with OS in FOLFIRI
treatment group (HR = 1.58; 95% CI = (1, 2.5); P = 0.05; N = 329); see S1 Fig panel C, D and E,
F, respectively.
Association between 5-FU profile and baseline characteristics
S5 Table part A shows associations between the 5-FU predictive profile and several baseline
clinicopathological characteristics for the PETACC-3 subpopulation. The table showing the
same information for the samples from the Kennedy cohort is available as S6 Table part A. It is
seen that T-stage has a significant association with the 5-FU profile in the PETACC-3 subpop-
ulation in the simple and in the multiple regression models. However, the effect is only statisti-
cally significant when comparing T1-2 (smallest group) to T3 (largest group). This was not
taken into consideration for the subsequent analysis. No particularities were noticed in the
Kennedy cohort. We do not have MSI/MSS information for the Kennedy cohort.
The 5-FU gene expression profile and patient prognosis
Table 1 and S5 Table part B display the results from the fitted (multivariable) Cox Proportional
Hazards models for the PETACC-3 subpopulation. Table 1 shows that the effect of the 5-FU
profile on outcome (RFS) was statistically significant even when correcting for a set of standard
clinicopathological variables (HR = 0.72, 95% CI = (0.62, 0.84), P = 0,00002, N = 558), with the
high scoring (sensitive) group having longer RFS.
As with the irinotecan profile in order to test for a potential interaction between the profile
score and the treatment group, we fitted models including an interaction term for RFS and for
5-FU and Irinotecan Predictive Biomarkers
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OS (outcome ~ treatment_group + profile_score + treatment_group:profile_score). For the
5-FU profile, only the HR for the profile score was statistically significantly different from 1
(for OS and RFS, see S5 Table part C for details). The treatment group and the interaction term
did not have an HR statistically significantly different from 1.
In Fig 1 Kaplan Meier curves are shown for the endpoint RFS (panel A) and OS (panel B).
In each panel the patients are stratified according to their 5-FU profile score. It is seen that the
score splits the patients into a good and a poor prognosis group. Patients classified as sensitive
had a statistically significantly better survival with RFS (HR = 0.54; 95% CI = (0.41, 0.71);
P = 7.87e-6; N = 636; based on dichotomized profile scores) and OS (HR = 0.47; 95% CI =
(0.34, 0.63), P = 7.4e−7; based on dichotomized profile scores), (see method section).
Subgroup analyses
The panels A in Figs 2 (RFS) and 3 (OS) display the data from patients in the “5-FU only” (no
irinotecan added) treatment group. It is seen that the 5-FU profile also significantly splitted the
patients in this treatment arm into a good and a poor prognosis subgroup with RFS in Fig 2
(HR = 0.57, 95% CI = (0.39, 0.85), P = 5.38e-3, N = 307) and OS in Fig 3 (HR = 0.52; 95% CI =
(0.33, 0.81); P = 3.03e-3; N = 307).
The same analysis was performed on the FOLFIRI treated patients (see panels B in Figs 2
and 3). It is seen that the 5-FU profile also splitted these patients into two significantly different
prognostic groups for RFS (HR = 0.50, 95% CI = (0.34, 0.74), P = 3.48e-4, N = 329) and OS
(HR = 0.42; 95% CI = (0.27, 0.65); P = 5.52e-5; N = 329).
Based on the above results showing a significant prognostic value of the 5-FU expression
profile in patients enrolled in the PETACC-3 study in which all patients received 5-FU, we
then applied the 5-FU profile to a cohort of CC patients who had no adjuvant therapy to sur-
gery, the Kennedy cohort. In the Kennedy cohort [21] no statistically significant differences
(univariate and multivariate analysis) in RFS (HR = 0.92; 95% CI = (0.64, 1.33); P = 0.671,
N = 359) or OS (HR = 0.96, 95% CI = (0.67, 1.4); P = 0.849; N = 359) were observed when the
population was dichotomized by the 5-FU predictive profile, see Fig 4. It was further checked
Table 1. Association between RFS and the 5-FU profile score in the subpopulation of the PETACC-3 study.
HR_multi CI_multi pval_multi HR_sing CI_sing pval_sing
FU5Pred (IQR scaled) 0.72 (0.62, 0.84) 0.00002 0.69 (0.6, 0.79) 0.00000
trt_grp (FOLFIRI vs 5-FU/FA) 0.87 (0.66, 1.14) 0.32012 0.87 (0.68, 1.12) 0.29253
age (in years) 1.00 (0.99, 1.01) 0.86710 1.00 (0.99, 1.01) 0.73414
sex (female vs male) 1.04 (0.78, 1.39) 0.76737 0.91 (0.7, 1.18) 0.46790
site (right vs left) 1.15 (0.86, 1.55) 0.34834 1.10 (0.85, 1.43) 0.47551
tstage (T12 vs T3) 0.60 (0.3, 1.19) 0.14288 0.41 (0.21, 0.8) 0.00894
tstage (T4 vs T3) 1.72 (1.23, 2.39) 0.00131 1.86 (1.38, 2.52) 0.00005
nstage (N2 vs N1) 1.98 (1.49, 2.63) 0.00000 2.21 (1.71, 2.85) 0.00000
grade (G-34 vs G-12) 1.57 (0.99, 2.49) 0.05639 1.57 (1.09, 2.27) 0.01570
BRAF (mut vs wt) 1.20 (0.68, 2.11) 0.53461 1.16 (0.7, 1.94) 0.55788
KRAS (mut vs wt) 1.51 (1.12, 2.03) 0.00620 1.29 (0.99, 1.68) 0.05835
MSI (MSI-H vs MSS) 0.46 (0.25, 0.82) 0.00835 0.60 (0.35, 1.03) 0.06384
The ﬁrst three columns relate to results from a multivariable Cox Proportional Hazards model. The last three columns relate to the results of each variable
being tested in a simple (single explanatory variable) Cox Proportional Hazards model. The 5-FU proﬁle score is statistically signiﬁcantly associated with
RFS, even when correcting for other covariates.
Full model: n = 558, number of events = 212, 78 observations deleted due to missingness.
doi:10.1371/journal.pone.0155123.t001
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Fig 1. PETACC-3 subpopulation of patients stratified by the 5-FU profile score. Patients with a 5-FU profile score smaller or equal to 50
were labeled as poor prognosis, the other ones as good prognosis in relation to 5-FU treatment. 5-FU was included in all patients' treatment.
The curves show that the 5-FU profile significantly separates the patients into good and poor outcome (using RFS as endpoint in panel A,
OS in panel B).
doi:10.1371/journal.pone.0155123.g001
Fig 2. PETACC-3 subpopulation of patients stratified by the 5-FU profile score, RFS. Same data as in Fig 1A, but presenting the
results per treatment arm. Panel A shows the data of the patients in the 5-FU/FA arm, Panel B the data for the patients in the FOLFIRI
treatment arm. The used endpoint is RFS.
doi:10.1371/journal.pone.0155123.g002
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Fig 3. PETACC-3 subpopulation of patients stratified by the 5-FU profile score, OS. Same data as in Fig 1B, but presenting the results
per treatment arm. Panel A shows the data of the patients in the 5-FU/FA arm, Panel B the data for the patients in the FOLFIRI treatment
arm. The used endpoint is OS.
doi:10.1371/journal.pone.0155123.g003
Fig 4. Patients from the Kennedy cohort stratified by the 5-FU profile score. Patients with a 5-FU profile score smaller or equal to 50
were labeled as low score, the other ones as high score in relation to 5-FU treatment. The curves show that the 5-FU profile does not
separate the CC patients into good and poor outcome (using RFS as endpoint in panel A, OS in panel B).
doi:10.1371/journal.pone.0155123.g004
5-FU and Irinotecan Predictive Biomarkers
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that also performing an analysis using the continuous profile score did not lead to statistically
significant differences in RFS (S6 Table part B) or OS (S6 Table part C).
We then asked if there was a significant difference in the hazard ratios for the 5-FU profile
for RFS in both treatment arms (5-FU and FOLFIRI) of the PETACC-3 (HR = 0.54; 95% CI =
(0.41, 0.71)) and for the Kennedy cohort (HR = 0.92; 95% CI = (0.64, 1.33)). A test comparing
the two hazard ratios demonstrated a significant difference (z-test, p = 0.02, see methods).
Discussion
In this study gene expression response profiles for irinotecan and 5-FU developed based on the
NCI60 cell line repository and filtered using clinical tumor material representing different
tumor types to exclude cell-line specific genes [18] were evaluated retrospectively in tumor
material obtained from the PETACC-3 prospective and randomized clinical trial [20] and in
publically available data from stage II CC patients, the Kennedy cohort [21].
MPI’s method uses the correlation between sensitivity to a drug and gene expression in a
panel of cell lines. The resulting gene expression profile of genes can explain the differential
sensitivity in vitro. But this gene expression profile is not directly predictive in a clinical setting.
To predict patient responses to the same drug, a translation from the in vitro profile to a clini-
cal profile is necessary. MPI filters the in vitro profile through a systems biological network
derived from analysis of patient samples.
For application to the clinical studies, the genes found to be markedly up- or down-regu-
lated in the profiles were translated by the MPI laboratory to corresponding ALMAC probe
sets in order to be tested in the two clinical data sets.
Using a prospective-retrospective trial design is considered necessary to reach a sufficient
level of evidence to determine clinical utility when validating predictive biomarkers [23]. The
design of the PETACC-3 trial allows for a direct validation of irinotecan predictive biomarkers
while it lacks an untreated arm to test biomarker candidates to predict benefit from 5-FU treat-
ment. A total of 636 stage III CC patients from the PETACC-3 study were included in the pres-
ent study.
The most interesting finding of the present study was that the 5-FU response profile signifi-
cantly separated the PETACC-3 patients into a larger group (79% of the patients) of good and
a smaller group (21% of the patients) of poor prognosis independently from the known prog-
nostic clinicopathological parameters TN stage, MSI/MSS-status, site, grade, and activating
mutations in KRAS and BRAF. In contrast, the irinotecan expression profile did not lead to a
statistically significant split. When dividing the present patient cohort according to treatment
arm, similar results were obtained, meaning that the irinotecan profile did not provide predic-
tive nor prognostic information.
The scaling of the profile was a linear transformation that does not affect the distribution
but only the interpretability of the score. The cutoff of 50 is close to the median in many popu-
lations, but in the stage III PETACC population it was far from the median. We had to stick to
the cutoff of 50, however, because this was defined in the statistical analysis plan before looking
at the clinical data.
Since patients in both treatment groups of the PETACC-3 trial received 5-FU, it is not possi-
ble to distinguish a profile indicative of smaller intrinsic risk from a profile predictive of a sur-
vival benefit due to 5-FU efficacy. A purely prognostic profile should recognize different risk
groups also in untreated populations. However, we did not observe any statistically significant
prognostic effect in the Kennedy cohort, not even a trend. This could be interpreted as the dif-
ference between good and poor survival groups in the PETACC-3 cohort as identified by the
5-FU profile, is mainly due to difference in benefit from 5-FU.
5-FU and Irinotecan Predictive Biomarkers
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An alternative interpretation is that the profile has a strong purely prognostic value in stage
III (PETACC-3) but not in stage II (Kennedy), or that the observation is due to other and
unknown differences between the two patient cohorts cannot be excluded.
A comparison of biomarker validation results from multiple data sets has several limita-
tions. In this study, first, the PETACC-3 subpopulation consisted of stage III CC patients, the
Kennedy cohort of stage II CC patients. Second, the set of available covariates was different
and some important characteristics, such as MSI status, were not always available. In the
PETACC-3 subpopulation there is an overrepresentation of male patients while in the Kennedy
cohort this is better balanced. Furthermore, the balance of left- versus right-sided tumors in
the PETACC-3 cohort and the Kennedy cohort differ (with many missing data on primary
tumor location for the patients of the Kennedy cohort).
It should be noted that finding suitable data sets to assess a potential predictive ability of a
biomarker for adjuvant 5-FU and/or irinotecan treatment in CC patients is difficult. Most stud-
ies comparing treatment with 5-FU to untreated patients were conducted many years ago
and the patient populations would not be representative of today’s CC patients anymore. For
example, among many improvements, surgical procedures have been significantly further
developed.
Despite the two cohorts being different, we asked if there was a significant difference in the
hazard ratios for the 5-FU profile for RFS in PETACC-3 (HR = 0.54; 95% CI = (0.41, 0.71))
and in the Kennedy cohort (HR = 0.92; 95% CI = (0.64, 1.33)) with a test comparing the two
hazard ratios which demonstrated a significant difference (z-test, p = 0.02). However, due to
major differences between the two analyzed cohorts, this result needs further clinical validation
in tumor material obtained from an appropriately designed clinical study.
The irinotecan profile failed to demonstrate any significant separation of the PETACC-3
patients or the Kennedy cohort. One explanation to this finding is that, since there was no sig-
nificant effect of adding treatment with irinotecan in the original PETACC-3 study, any sub-
population that would benefit from adding irinotecan might be too small to be detected with
the available patient samples. Another explanation that cannot be excluded is that there is no
benefit from adjuvant irinotecan treatment in stage III CC. This latter explanation is supported
by the CALGB 89803 study which had a similar design as the PETACC-3 study and which also
failed to demonstrate any significant benefit from addition of irinotecan to LV5FU [24].
Adjuvant treatment of CC patients in stage II or III has stagnated even with many attempts
of introducing new drugs during the past decade [25]. Biomarkers to assist the physician in
regards of prognosis, of prediction of treatment efficacy and expected severe toxicities to anti-
neoplastic treatment of CC have long been eagerly awaited. Only few prognostic biomarkers
have been implemented clinically and no biomarkers for 5-FU or irinotecan sensitivity have
been developed to a stage where they can be used in routine treatment of CC. An important
issue with the validation of biomarkers in adjuvant treatment of CC is that patients not
experiencing a disease recurrence could either have been cured by the primary surgery (repre-
senting sensitive or resistant tumors) or by the subsequent chemotherapy (representing sensi-
tive tumors), while patients having disease recurrence are considered to have resistant tumors.
This is an inherent problem to which there is no satisfying solution when analyzing predictive
biomarkers in the adjuvant setting.
In conclusion, the present study presents a novel 5-FU mRNA expression profile which
could separate the stage III subpopulation of the PETACC-3 patient cohort into subgroups
with statistically significant different outcome. By also applying this profile to a cohort of
untreated CC patients, we here provide suggestions for a possible association between the 5-FU
profile and benefit from adjuvant 5-FU treatment in stage III CC patients. We are currently
seeking to validate our 5-FU data in an independent patient cohort.
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Supporting Information
S1 Doc. Data Processing in PETACC-3 data. The document describes human sample mate-
rial and data processing with R statistical software on the PETACC-3 data.
(DOCX)
S1 Fig. PETACC-3 subpopulation of patients stratified by their irinotecan profile score.
Patients with an irinotecan profile score smaller or equal to 50 were labeled as poor prognosis,
the other ones as good prognosis in relation to 5-FU treatment. The curves show that the irino-
tecan profile does not split the patients into good and poor outcome (using RFS as endpoint in
panel A, OS in panel B). Panels C and D show the same data as in panel A, but presenting the
results per treatment arm. Panel C shows the data of the patients in the 5-FU/FA arm, Panel D
the data for the patients in the FOLFIRI treatment arm. The used endpoint is RFS. Panels E
and F show the same data as in panel B, but presenting the results per treatment arm. Panel E
shows the data of the patients in the 5-FU/FA arm, Panel F the data for the patients in the FOL-
FIRI treatment arm. The used endpoint is OS.
(PDF)
S1 Table. Probe sets in the irinotecan profile. Part A. Probe sets for genes overexpressed in
cell lines sensitive to irinotecan. The table shows the Almac probe sets that corresponds to the
genes identified in cell lines. Note that some genes have several matching probe sets, the map-
ping is neither unique nor inambiguous. Part B. Probe sets for genes overexpressed in cell
lines resistant to irinotecan. The table shows the Almac probe sets that corresponds to the
genes identified in cell lines. Note that some genes have several matching probe sets, the map-
ping is neither unique nor inambiguous.
(PDF)
S2 Table. Probe sets in the 5-FU profile. Part A. Probe sets for genes overexpressed in cell
lines sensitive to 5-FU. The table shows the Almac probe sets that corresponds to the genes
identified in cell lines. Note that some genes have several matching probe sets, the mapping is
neither unique nor inambiguous. Part B. Probe sets for genes overexpressed in cell lines
resistant to 5-FU. The table shows the Almac probe sets that corresponds to the genes identi-
fied in cell lines. Note that some genes have several matching probe sets, the mapping is neither
unique nor unambiguous.
(PDF)
S3 Table. Baseline demographics. Part A. Baseline demographics for the patients from the
PETACC-3 study. The table provides an overview of the distribution of all patients in the
PETACC-3 study according to the major clinicopathological variables. Some variables were
only assessed in the profiled samples. This information is provided in italics. For example, the
KRAS mutation status was not assessed in most of the samples (1395 missing values). Hence,
the information that only 24% of the samples are wild-type is somewhat misleading: In italics,
one can see that among the assessed samples, 60.4% were found to be wild-type and 39.4% to
be KRAS mutated. Part B. Baseline demographics for the subset of stage III patients from
the PETACC-3 study selected for the present analysis. The table provides an overview of the
distribution of the PETACC-3 patients used in the present analysis according to the major
clinicopathological variables. The information provided in italics shows the actual percentages
among all samples without missing values. For example, the KRAS mutation status was not
assessed in 40 samples (6.3% of the patients). Hence, the information that only 55.7% of the
samples are wild-type can be misleading. In italics, one can see that actually 59.4% of the
assessed samples were found to be wild-type and 40.6% to be KRAS mutated. Part C. Baseline
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demographics for the stage II CC patients from Kennedy et al [21]. The table provides an
overview of the distribution of all (stage II) patients in the study published in Kennedy et al
[21] according to the major clinicopathological variables.
(PDF)
S4 Table. Irinotecan profile. Part A. Association between the irinotecan profile score and
clinicopathological parameters for the PETACC-3 subpopulation.We tested for association
between the irinotecan profile score and the major clinicopathological parameters in the clini-
cal data. It is seen that site, grade and MSI has a significant association with the irinotecan pro-
file score in the PETACC-3 subpopulation in the simple and in the multiple regression models.
Detailed results are provided in the table below. The first two columns relate to the results from
a multivariable regression model. The last two columns relate to the results of each variable
being tested in a simple (single explanatory variable) model. The estimates for the intercepts
are not reported. Part B. Association between RFS and the irinotecan profile score in the
subpopulation of the PETACC-3 study. The first three columns relate to results from a multi-
variable Cox Proportional Hazards model. The last three columns to the results of each variable
was tested in a simple (single explanatory variable) Cox Proportional Hazards model. The iri-
notecan profile score was not statistically significantly associated with RFS. The estimates for
the other variables are in line with results obtained in former analyses on the PETACC-3 data.
Part C. Association between OS and the irinotecan profile score in the subpopulation of
the PETACC-3 study. The first three columns relate to results from a multivariable Cox Pro-
portional Hazards model. The last three columns to the results of each variable was tested in a
simple (single explanatory variable) Cox Proportional Hazards model. The irinotecan profile
score was not statistically significantly associated with OS. Part D. Interaction between the iri-
notecan profile score and the treatment group, RFS and OS. In order to test for a potential
interaction between the profile score and the treatment group, we fitted models for RFS and
for OS including an interaction term (outcome ~ treatment_group + profile_score + treat-
ment_group:profile_score). For the irinotecan profile, none of the three terms in the model
showed a HR statistically significantly different from 1.
(PDF)
S5 Table. 5-FU profile in PETACC-3. Part A. Association between the 5-FU profile score
and clinicopathological parameters for the PETACC-3 subpopulation.We tested for associ-
ation between the 5-FU profile score and the major clinicopathological parameters in the
clinical data. It is seen that T stage has a significant association with the 5-FU profile in the
PETACC-3 subpopulation in the simple and in the multiple regression models. However, the
effect is only statistically significant when comparing T1-2 (smallest group) to T3 (largest
group). Detailed results are provided in the table below. The first two columns relate to the
results from a multivariable regression model. The last two columns relate to the results of each
variable being tested in a simple (single explanatory variable) model. The estimates for the
intercepts are not reported. Part B. Association between OS and the 5-FU profile score in
the subpopulation of the PETACC-3 study. The first three columns relate to results from a
multivariable Cox Proportional Hazards model. The last three columns relate to the results of
each variable being tested in a simple (single explanatory variable) Cox Proportional Hazards
model. The 5-FU profile score is statistically significantly associated with OS, even when cor-
recting for other covariates. Part C. Interaction between the 5-FU profile score and the treat-
ment group, RFS and OS. In order to test for a potential interaction between the profile score
and the treatment group, we fitted models for RFS and for OS including an interaction term
(outcome ~ treatment_group + profile_score + treatment_group:profile_score). For the 5-FU
profile, only the HR of the profile score was statistically significantly different from 1 after
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adjustment for the other explanatory variables in the model. The treatment group and the
interaction term did not have a HR statistically significantly different from 1.
(PDF)
S6 Table. 5-FU profile in the Kennedy cohort. Part A. Association between the 5-FU profile
score and clinicopathological parameters for the samples from the Kennedy cohort. The
first two columns relate to the results from a multivariable regression model. The last two col-
umns relate to the results of each variable being tested in a simple (single explanatory variable)
model. The estimates for the intercepts are not reported in the table below. The only statisti-
cally significant association found is with 'age'. Part B. Association between relapse free sur-
vival and the 5-FU profile score in the Kennedy cohort. The first three columns relate to
results from a multivariable Cox Proportional Hazards model. The last three columns relate to
the results of each variable being tested in a simple (single explanatory variable) Cox Propor-
tional Hazards model. The 5-FU profile score was not statistically significantly associated with
RFS. Part C. Association between overall survival and the 5-FU profile score in the Kennedy
cohort. The first three columns relate to results from a multivariable Cox Proportional Haz-
ards model. The last three columns relate to the results of each variable being tested in a simple
(single explanatory variable) Cox Proportional Hazards model. The 5-FU profile score was not
statistically significantly associated with OS.
(PDF)
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